Jingying Qiu1,
Chengjiang Li2,
Zhichun Dong1,
Jing Wang1 
For correspondence:- Jing Wang Email: wjing0525@163.com Tel:+8657583338312
Accepted: 21 May 2020 Published: 30 June 2020
Citation: Qiu J, Li C, Dong Z, Wang J. Anti-diabetic effect of a monoamine oxidase inhibitor (tranylcypromine) in rats with poorly-controlled blood glucose levels: A potential and novel therapeutic option for diabetes. Trop J Pharm Res 2020; 19(6):1249-1254 doi: 10.4314/tjpr.v19i6.20
© 2020 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..
Purpose: To determine the anti-diabetic effect of a monoamine oxidase inhibitor (tranylcypromine) in sulphonyl urea-refractory rats with poorly-controlled blood glucose levels.
Methods: Alloxan-induced diabetic Wistar rats were assigned to two groups (30 rats/group). One group received glibenclamide at a dose of 0.6 mg/kg, while the other group was given monoamine oxidase inhibitor (tranylcypromine) at a dose of 5 mg/day. The two groups were treated for 2 weeks. Blood samples were collected at baseline (before treatment) and at the end of treatment for determination of plasma glucose (fasting and fed), hemoglobin A1c, lipid profiles (serum total cholesterol, very-low-density lipoprotein, low-density lipoprotein, high-density lipoprotein and triglycerides); oxidative stress parameters (anti-oxidant enzymes), insulin levels, and some hepatic enzymes of glucose metabolism.
Results: Monoamine oxidase inhibitor treatment resulted in significant decrease in the levels of blood glucose, HbA1c, and lipid levels from baseline, relative to glibenclamide (p < 0.05). Greater improvements in oxidative stress biomarkers (glutathione and superoxide dismutase), insulin levels and hepatic enzymes of glucose metabolism were observed in monoamine oxidase inhibitor group than in glibenclamide group (p < 0.05). Oxidative stress was significantly inhibited by monoamine oxidase inhibitor via increases in glutathione (GSH) level and superoxide dismutase (SOD) activity, when compared to glibenclamide (p < 0.05).
Conclusion: These results suggest that monoamine oxidase inhibitor may be a better treatment option for diabetes than glibenclamide.
Archives
News Updates
Fulltext in PDF